Copyright
©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. May 21, 2005; 11(19): 2892-2899
Published online May 21, 2005. doi: 10.3748/wjg.v11.i19.2892
Published online May 21, 2005. doi: 10.3748/wjg.v11.i19.2892
Table 12 Changes in serum P-III-P, IV-C contents between two groups before and after treatment.
| Time points | Group | n | P-III-P (mg/L) | IV-C (mg/L) | ||||
| Median of differential | Standard deviation | Percent of difference | Median of difference | Standard deviation | Percent of difference | |||
| 12-wk treatment | Experimental | 110 | -2.2b | 5.0 | -20.1 | -25.0a | 128.2 | -39.3 |
| Control | 106 | -0.0 | 5.0 | -1.3 | -6.5 | 87.0 | -9.1 | |
| 24-wk treatment | Experimental | 110 | -2.9b | 4.6 | -33.9 | -33.0a | 139.1 | -48.3 |
| Control | 106 | -0.3 | 5.5 | -3.0 | -14.0 | 80.4 | -18.6 | |
- Citation: Liu P, Hu YY, Liu C, Xu LM, Liu CH, Sun KW, Hu DC, Yin YK, Zhou XQ, Wan MB, Cai X, Zhang ZQ, Ye J, Zhou RX, He J, Tang BZ. Multicenter clinical study on Fuzhenghuayu capsule against liver fibrosis due to chronic hepatitis B. World J Gastroenterol 2005; 11(19): 2892-2899
- URL: https://www.wjgnet.com/1007-9327/full/v11/i19/2892.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i19.2892